Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Date:6/12/2008

l drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins for the treatment of cancer. In addition, HGS has substantial financial rights to three products in the GlaxoSmithKline clinical development pipeline.

To view the EULAR oral presentation reporting results of the Phase 2 long- term continuation study of LymphoStat-B through three years, click here. To view the EULAR poster presentation reporting the safety profile of LymphoStat- B through three years, click here. To view the EULAR poster presentation reporting the progressive normalization of autoantibody, immunoglobulin and complement levels over three years of treatment with LymphoStat-B, click here. To view the EULAR poster presentation reporting evidence of LymphoStat-B's potential steroid-sparing activity, click here. For more information on LymphoStat-B, visit http://www.hgsi.com/belimumab.html. For more information on lupus, visit the Lupus Foundation of America at http://www.lupus.org or the European Lupus Erythematosus Federation at http://www.elef.rheumanet.org . For more information about HGS, visit
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
3. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
6. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
(Date:8/19/2014)... , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today ... Annual Meeting of the American Academy of ... Care Surgery in Philadelphia, Pennsylvania ... The presentation will report results from a recently ...
Breaking Medicine Technology:AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... NEW YORK, Oct. 31 A recent outbreak ... to,as "the superbug," should cause organizations and facilities ... The superbug is resistant to common antibiotics. ... abscesses, boils and other pus-filled,lesions. Superbug infections prior ...
... Oct. 31 United,Therapeutics Corporation (Nasdaq: UTHR ... today that they will release the results of ... formulation of treprostinil,in pulmonary arterial hypertension (PAH) before ... Therapeutics will expand its previously scheduled conference,call on ...
Cached Medicine Technology:'Superbug' Outbreak Calls for Immediate Increased Attention on Infection Control 2Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
(Date:8/20/2014)... IQ Formulations , a top national health ... Inc. 500 , distinguishing it as one of the fastest ... only made the list, but was ranked in the top ... three years. It also ranked ninth among all health companies, ... second fastest growing company in the Miami metro area. ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... Awards. PM360, a leading health-marketing industry trade magazine, will ... 2009, the Trailblazer Awards are given to outstanding companies, ... has to offer. , “We are proud to ... our call to entries with double the number of ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... world’s largest nutrition school, is proud to announce ... Integral Studies (CIIS), a cutting-edge university offering ... Nutrition’s Health Coach Training Program are now eligible ... of Arts in Integrative Health Studies. , “I’m ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3
... cohort studies on the association of alcohol consumption with colorectal ... 2 from Australia, 13 from Western Europe, and 24 from ... least at higher levels of consumption, is associated with an ... was no increase in the risk for consumers reporting an ...
... , TUESDAY, Sept. 13 (HealthDay News) --The lifestyle changes ... disease may also improve sexual function in men with ... from the Mayo Clinic in Rochester, Minn., analyzed six ... determine how lifestyle changes and drugs used to treat ...
... for an effective vaccine and treatment against the potentially fatal ... the discovery of two ,Achilles, heels, within the virus. ... South Wales (UNSW) studied individuals at high risk of HCV ... the onset of infection. Using a new technique ...
... Canadian researchers has found the first evidence that lifelong ... While hearing studies have already shown that trained musicians ... is the first study to examine hearing abilities in ... 18 to 91 years of age. The study ...
... HealthDay Reporter , MONDAY, Sept. 12 (HealthDay News) -- ... become fathers, perhaps because they don,t need to compete with ... with their children. The findings don,t prove that fatherhood ... hormonal systems in men may detect that they,ve become fathers ...
... MONDAY, Sept. 12 (HealthDay News) -- Implantable electronic devices ... heart conditions and save lives, but these benefits may ... complications, a new study suggests. Researchers from the ... that people who develop an infection related to a ...
Cached Medicine News:Health News:Relation of alcohol consumption to colorectal cancer 2Health News:Breakthrough opens new avenues for hep C vaccine 2Health News:Science finding is music to the ears 2Health News:Testosterone Levels Seem to Fall With Fatherhood 2Health News:Testosterone Levels Seem to Fall With Fatherhood 3Health News:Heart Devices Like Pacemakers Linked to Infections 2
Inquire...
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
Medicine Products: